Dow Up0.19% Nasdaq Up0.56%

ImmunoCellular Therapeutics, Ltd. (IMUC)

0.65 Up 0.02(3.17%) 4:02PM EST
ProfileGet Profile for:
ImmunoCellular Therapeutics, Ltd.
23622 Calabasas Road
Suite 300
Calabasas, CA 91302
United States - Map
Phone: 818-264-2300
Fax: 818-224-5287

Index Membership:N/A
Full Time Employees:3

Business Summary 

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of brain and ovarian cancers. Its lead product candidate includes ICT-107, a dendritic cell (DC) vaccine that completed completed Phase II testing trials for the treatment of glioblastoma multiforme (GBM). The company also develops other therapeutic DC vaccines, such as ICT-121 to treat recurrent GBM and other solid tumor cancers, as well as ovarian, pancreatic, and breast cancers; and ICT-140 that targets 7 tumor-associated antigens expressed on ovarian cancer cells. In addition, it has a differential immunization for antigen and antibody discovery platform for discovering monoclonal antibodies for therapeutic and diagnostic development. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on ImmunoCellular Therapeutics, Ltd.

Corporate Governance 
ImmunoCellular Therapeutics, Ltd.’s ISS Governance QuickScore as of Jul 1, 2013 is 8. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 2; Compensation: 7.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. John S. Yu M.D., Ph.D., 50
Founder, Chairman, Chief Scientific Officer and Corp. Sec.
Mr. Andrew Gengos , 50
Chief Exec. Officer, Pres and Director
Mr. David E. Fractor CPA, 54
Chief Financial Officer, Principal Accounting Officer, VP of Fin. and Treasurer
Dr. Anthony J. Gringeri Ph.D., 60
Sr. VP of Strategic Resources
Mr. Sanford J. Hillsberg Esq., J.D., 66
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders